This thesis investigates alternative models for financing pharmaceutical research and development (R&D), focusing on equity crowdfunding, blockchain-enabled decentralized governance, and traditional M&A strategies. Drawing on three distinct studies, it analyzes the potential of crowdfunding to support early-stage innovation, explores the role of Decentralized Autonomous Organizations (DAOs) as governance structures rather than funding vehicles, and evaluates how large pharmaceutical firms perceive and integrate emerging technologies within their acquisition strategies. While these models offer promising mechanisms to address inefficiencies in traditional funding structures, challenges remain in terms of scalability, regulation, and operational integration. The thesis concludes that alternative and decentralized models may complement—but not replace—traditional pharmaceutical financing, particularly in bridging early-stage capital gaps.
Questa tesi esplora modelli alternativi per il finanziamento della ricerca e sviluppo (R&S) farmaceutica, con particolare attenzione all’equity crowdfunding, alla governance decentralizzata tramite blockchain e alle strategie tradizionali di fusioni e acquisizioni (M&A). Attraverso tre studi distinti, analizza il potenziale del crowdfunding per sostenere l’innovazione nelle fasi iniziali, esamina il ruolo delle Decentralized Autonomous Organizations (DAO) come strutture di governance e valuta come le grandi aziende farmaceutiche percepiscono e integrano le tecnologie emergenti nelle loro strategie di acquisizione. Sebbene questi modelli offrano meccanismi promettenti per affrontare le inefficienze delle strutture tradizionali di finanziamento, persistono sfide in termini di scalabilità, regolamentazione e integrazione operativa. La tesi conclude che i modelli alternativi e decentralizzati possono affiancare—ma non sostituire—i modelli tradizionali, in particolare per colmare i gap di capitale nelle fasi iniziali.
Decentralized funding in pharma : how alternative models for drug r and d financing and governance could reshape innovation, investment, and healthcare affordability
FANTACCINI, SIMONE
2024/2025
Abstract
This thesis investigates alternative models for financing pharmaceutical research and development (R&D), focusing on equity crowdfunding, blockchain-enabled decentralized governance, and traditional M&A strategies. Drawing on three distinct studies, it analyzes the potential of crowdfunding to support early-stage innovation, explores the role of Decentralized Autonomous Organizations (DAOs) as governance structures rather than funding vehicles, and evaluates how large pharmaceutical firms perceive and integrate emerging technologies within their acquisition strategies. While these models offer promising mechanisms to address inefficiencies in traditional funding structures, challenges remain in terms of scalability, regulation, and operational integration. The thesis concludes that alternative and decentralized models may complement—but not replace—traditional pharmaceutical financing, particularly in bridging early-stage capital gaps.File | Dimensione | Formato | |
---|---|---|---|
Fantaccini_Simone_Thesis.pdf
non accessibile
Dimensione
1.7 MB
Formato
Adobe PDF
|
1.7 MB | Adobe PDF | Visualizza/Apri |
I documenti in POLITesi sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/10589/237137